Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 8,375 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

NCT04939467
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet
Drug
Lead sponsor
Blade Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 22, 2026, 7:10 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Donepezil Memory Preservation Post ECT

NCT02331771
View directory record Official record
Conditions
Memory Impairment
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Porter Adventist Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food-Effect of H3B-6527

NCT03424577
View directory record Official record
Conditions
Healthy Participants
Interventions
H3B-6527
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

NCT01443481
View directory record Official record
Conditions
Solid Tumors, Hepatic Impairment
Interventions
Dovitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 22, 2026, 7:10 PM EDT
Completed No phase listed Observational

Opicapone Treatment Initiation Open-Label Study

NCT04787965
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 3 Interventional

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

NCT00578695
View directory record Official record
Conditions
Hyponatremia
Interventions
lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of TD-1439 in Healthy Subjects

NCT02903095
View directory record Official record
Conditions
Healthy Subjects
Interventions
TD-1439, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

NCT00801684
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

NCT05567952
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir, placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
67
States / cities
Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 22, 2026, 7:10 PM EDT
Terminated Phase 2 Interventional Results available

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

NCT00302952
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lovastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate

NCT00999297
View directory record Official record
Conditions
Obesity, Weight
Interventions
Dihydrocapsiate
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Actions of Omega-3 Fatty Acids

NCT01896414
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
EPA (marine fatty acids), Placebo
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 3 Interventional Results available

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

NCT01463306
View directory record Official record
Conditions
Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 66 Years
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

NCT04056455
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients

NCT01025817
View directory record Official record
Conditions
Kidney Transplant
Interventions
Everolimus and tacrolimus, mycophenolate mofetil and tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 3 Interventional Results available

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

NCT02231749
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, Sunitinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
37
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 22, 2026, 7:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NCT07109726
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Interventions
TER-2013, Fulvestrant injection
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Lipoic Acid as a Treatment for Acute Optic Neuritis

NCT01294176
View directory record Official record
Conditions
Optic Neuritis
Interventions
Lipoic Acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

NCT05002140
View directory record Official record
Conditions
Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions
XRD-0394, Palliative radiotherapy
Drug · Radiation
Lead sponsor
XRad Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

NCT00692640
View directory record Official record
Conditions
Cancer, Non-small Cell Lung Cancer
Interventions
XL147 (SAR245408), Erlotinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib followed by treatment-free
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

NCT04976855
View directory record Official record
Conditions
Healthy Volunteer, Opioid-use Disorder
Interventions
INDV-2000, Placebo, SUBOXONE® sublingual film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 22, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study

NCT01220817
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
3 POMx capsules, 1 POMx capsule
Drug
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 22, 2026, 7:10 PM EDT